Advertisement

Topics

Standard & Poor’s Company Profile

06:42 EDT 23rd March 2019 | BioPortfolio

This Standard & Poor’s service provides factual research coverage enabling information about CRH Medical Corp and other securities to reach a wide investor audience of Buy and Sell-side investors, helping them understand a company’s fundamentals and business prospects. Currently profiling over 500 issuers, S&P Factual Stock Reports increase market awareness for issuers in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, Industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks.


News Articles [660 Associated News Articles listed on BioPortfolio]

Major new report connects North’s poor health with poor productivity

The North’s poor productivity connected to health for first time Outlines a new way of tackling productivity issues in UK through health Tackling North’s health could generate an additional £13.2...

Health Tip: Change Poor Posture

-- Everyone has back pain at some point, whether due to poor posture, heavy lifting, a spinal condition present a birth, or an exercise-related injury. While other triggers for back pain may not be as...

Unhealthy diet linked to poor mental health

A study has found that poor mental health is linked with poor diet quality -- regardless of personal characteristics such as gender age, education, age, marital status and income level.

The Heartbreaking Truth About Poor Cardiac Arrest Patients

FRIDAY, Nov. 30, 2018 -- Ambulance response times for cardiac arrest are longer in poor U.S. neighborhoods than in rich ones, which means poor patients are more likely to die, a new study finds. "When...

Standard Bariatrics receives FDA indication for No. 1 bariatric surgical procedure

(CincyTech) Standard Bariatrics, an innovator of surgical devices, has received a sleeve gastrectomy indication from the Food and Drug Administration (FDA) for the STANDARD CLAMP®. 'Standard Bariatri...

Standard Bariatrics receives FDA indication for #1 bariatric surgical procedure

(CincyTech) Standard Bariatrics, an innovator of surgical devices, has received a sleeve gastrectomy indication from the Food and Drug Administration (FDA) for the STANDARD CLAMP®. "Standard Bariatri...

Cancer Reference Standard

Horizon Discovery The Myeloid DNA Reference Standard is the first-to-mar­ket, large cell-line derived, myeloid cancer reference standard designed to enable faster, more reliable, and more cost-effect...

Hearing Aid Upkeep Often Out of Reach for the Poor

TUESDAY, Jan. 8, 2019 -- If you're poor, you'll likely have less success with your hearing aid, a new study finds. A survey of more than 1,100 Medicare recipients with hearing aids found that 27 perce...

Drugs and Medications [0 Results]

None

PubMed Articles [906 Associated PubMed Articles listed on BioPortfolio]

Uteroplacental and Fetal 4D Flow MRI in the Pregnant Rhesus Macaque.

Pregnancy complications are often associated with poor uteroplacental vascular adaptation and standard diagnostics are unable to reliably quantify flow in all uteroplacental vessels and have poor sens...

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 146...

First - line, non - cryopreserved autologous stem cell transplant for poor - risk germ - cell tumors: Experience in a developing country.

The current first - line treatment for non - seminomatous germ cell tumor (NSGCT) consists of four cycles of cisplatin, etoposide, and bleomycin (BEP), which results in 5 - year overall survival < 60%...

Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges.

Patients with unresectable metastatic colorectal cancer live for a median of three years when treated with standard therapies. While the evidence guiding cancer-directed treatment of this disease come...

Ultrapure Graphene Is a Poor Electrocatalyst: Definitive Proof of the Key Role of Metallic Impurities in Graphene Based Electrocatalysis.

Graphene and its derivatives have been reported in many articles as "metal-free" carbon electrocatalytic materials. Its synthesis procedures are generally based on chemical oxidation of graphite and s...

Clinical Trials [4110 Associated Clinical Trials listed on BioPortfolio]

Comparison of Treatment Modalities in Poor Responders Undergoing IVF

The accurate identification and efficient management of poor responders remains one of the most enigmatic challenges in assisted reproductive technology (ART). The investigators study will...

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cel...

Benefits of Standard ONS in Indian Adults

This is a prospective, single arm, baseline-controlled multicenter study to observe benefits on Oral Nutritional Supplement (ONS) intake in adults with medical conditions associated with p...

Prospective Randomized Trial Comparing Corifollitropin-alfa Late Start vs. Corifollitropin-alfa Standard Start in Expected Poor, Normal and High-responders Undergoing IVF

To compare the number of retrieved oocytes in the late start CF-alfa (day 4) versus standard CF-alfa protocols (day 2) in patients undergoing IVF. The primary analysis will be also perform...

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients

In this study we intend to treat patients with chronic hepatitis C of genotype 2 or 3 having characteristics associated with poor treatment response for additional 12 or 24 weeks beyond th...

Companies [737 Associated Companies listed on BioPortfolio]

Standard & Poor's

As the world's largest producer of independent equity research, Standard & Poor's licenses its research to global institutions for their investors and advisors. Standard & Poor's team of experienced ...

Allied World Assurance Company Holdings, AG

Allied World Assurance Company Holdings, AG, through its subsidiaries and brand known as Allied World, is a global provider of innovative property, casualty and specialty insuranc...

Standard & Poor’s

This Standard & Poor’s service provides factual research coverage enabling information about CRH Medical Corp and other securities to reach a wide investor audience of Buy an...

Rotation Medical Inc.

Rotator cuff damage is the most common source of shoulder pain, affecting more than 4 million people annually in the U.S. Traditional approaches to treating degenerate or torn rot...

ChildFund International

“Children often suffer the most because of limited access to clean water and poor sanitation,” said Sarah Bouchie, vice president for program development of ChildFund ...

More Information about "Standard & Poor’s" on BioPortfolio

We have published hundreds of Standard & Poor’s news stories on BioPortfolio along with dozens of Standard & Poor’s Clinical Trials and PubMed Articles about Standard & Poor’s for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Standard & Poor’s Companies in our database. You can also find out about relevant Standard & Poor’s Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record